Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors

Bibliography

• OLSHANSKY SJ, PASSARO DJ, HERSHOW RC et al.: A potential decline in life expectancy in the United States in the 21st century. N. Engl. J. Med. (2005) 352(11):1138-1145.
   Google Scholar
• HEDLEY AA, OGDEN CL, JOHNSON CL, CARROLL MD, CURTIN LR, FLEGAL KM: Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. J. Am. Med. Assoc. (2004) 291(23):2847-2850.
   PubMed Web of Science ®Google Scholar
• YUSUF S, HAWKEN S, OUNPUU S et al.: Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet (2005) 366(9497):1640-1649.
   Google Scholar
• LYON CJ, LAW RE, HSUEH WA: Minireview: adiposity, inflammation, and atherogenesis. Endocrinology (2003) 144(6):2195-2200.
   Google Scholar
• ECKEL RH: Obesity. Circulation (2005) 111(15):e257-e259.
   Google Scholar
• EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS: Executive summary of the third report of the National Cholesterol Education Program (NCEP). Adult Treatment Panel III. J. Am. Med. Assoc. (2001) 285(19):2486-2497.
   PubMed Web of Science ®Google Scholar
• ISOMAA B, ALMGREN P, TUOMI T et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care (2001) 24(4):683-689.
   Google Scholar
• Cigarette smoking and health. American Thoracic Society. Am. J. Respir. Crit. Care Med. (1996) 153(2):861-865.
   PubMed Web of Science ®Google Scholar
• CENTERS FOR DISEASE CONTROL AND PREVENTION: Cigarette Smoking Among Adults–United States, 2004. Morbidity and Mortality Weekly Report (2005) 54(44):1121–1124.
   Google Scholar
• ERIKSSON KF, LINDGARDE F: No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmo Preventive Trial with diet and exercise. Diabetologia (1998) 41(9):1010-1016.
   Google Scholar
• WADDEN TA, ANDERSON DA, FOSTER GD: Two-year changes in lipids and lipoproteins associated with the maintenance of a 5% to 10% reduction in initial weight: some findings and some questions. Obes. Res. (1999) 7(2):170-178.
   PubMedGoogle Scholar
• FLUM DR, SALEM L, ELROD JA, DELLINGER EP, CHEADLE A, CHAN L: Early mortality among Medicare beneficiaries undergoing bariatric surgical procedures. J. Am. Med. Assoc. (2005) 294(15):1903-1908.
   Web of Science ®Google Scholar
• BUCHWALD H, AVIDOR Y, BRAUNWALD E et al.: Bariatric surgery: a systematic review and meta-analysis. J. Am. Med. Assoc. (2004) 292(14):1724-1737.
   PubMed Web of Science ®Google Scholar
• ISO H, YAMAMOTO A, TOYOSHIMA H et al.: Smoking cessation and mortality from cardiovascular disease among Japanese men and women: the JACC Study. Am. J. Epidemiol. (2005) 161(2):170-179.
   PubMed Web of Science ®Google Scholar
• GOLDENBERG I, JONAS M, TENENBAUM A et al.: Current smoking, smoking cessation, and the risk of sudden cardiac death in patients with coronary artery disease. Arch. Intern. Med. (2003) 163(19):2301-2305.
   PubMed Web of Science ®Google Scholar
• KARNATH B: Smoking cessation. Am. J. Med. (2002) 112(5):399-405.
   PubMed Web of Science ®Google Scholar
• SILAGY C, LANCASTER T, STEAD L, MANT D, FOWLER G: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. (2004) 3:CD000146.
   PubMedGoogle Scholar
• HURT RD, SACHS DP, GLOVER ED et al.: A comparison of sustained-release bupropion and placebo for smoking cessation. N. Engl. J. Med. (1997) 337(17):1195-1202.
   PubMed Web of Science ®Google Scholar
• O'HARA P, CONNETT JE, LEE WW, NIDES M, MURRAY R, WISE R: Early and late weight gain following smoking cessation in the Lung Health Study. Am. J. Epidemiol. (1998) 148(9):821-830.
   PubMed Web of Science ®Google Scholar
• STAMPFER MJ, HU FB, MANSON JE, RIMM EB, WILLETT WC: Primary prevention of coronary heart disease in women through diet and lifestyle. N. Engl. J. Med. (2000) 343(1):16-22.
   PubMed Web of Science ®Google Scholar
• BRAUNWALD E, ANTMAN EM, BEASLEY JW et al.: ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J. Am. Coll. Cardiol. (2002) 40(7):1366-1374.
   PubMed Web of Science ®Google Scholar
• NADITCH MP: Acute adverse reactions to psychoactive drugs, drug usage, and psychopathology. J. Abnorm. Psychol. (1974) 83(4):394-403.
   PubMed Web of Science ®Google Scholar
• MATSUDA LA, LOLAIT SJ, BROWNSTEIN MJ, YOUNG AC, BONNER TI: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 346(6284):561-564.
   Google Scholar
• MUNRO S, THOMAS KL, ABU-SHAAR M: Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 365(6441):61-65.
   Google Scholar
• HERKENHAM M, LYNN AB, LITTLE MD et al.: Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA (1990) 87(5):1932-1936.
   PubMed Web of Science ®Google Scholar
• BENSAID M, GARY-BOBO M, ESCLANGON A et al.: The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol. (2003) 63(4):908-914.
   PubMed Web of Science ®Google Scholar
• BONZ, A, LASER M, KULLMER S et al.: Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J. Cardiovasc. Pharmacol. (2003) 41(4):657-664.
   PubMed Web of Science ®Google Scholar
• LIU J, GAO B, MIRSHAHI F et al.: Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem. J. (2000) 346(Part 3):835-840.
   PubMed Web of Science ®Google Scholar
• ISHAC EJ, JIANG L, LAKE KD, VARGA K, ABOOD ME, KUNOS G: Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br. J. Pharmacol. (1996) 118(8):2023-2028.
   PubMed Web of Science ®Google Scholar
• HANUS, L, BREUER A, TCHILIBON S et al.: HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. Proc. Natl. Acad. Sci. USA (1999) 96(25):14228-14233.
   PubMed Web of Science ®Google Scholar
• ASHTON JC, FRIBERG D, DARLINGTON CL, SMITH PF: Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. Neurosci. Lett. (2005) (In Press).
   PubMedGoogle Scholar
• FRIDE E, FOOX A, ROSENBERG E et al.: Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a ‘CB3’ receptor. Eur. J. Pharmacol. (2003) 461(1):27-34.
   PubMed Web of Science ®Google Scholar
• WILSON RI, NICOLL RA: Endocannabinoid signaling in the brain. Science (2002) 296(5568):678-682.
   Google Scholar
• GIUFFRIDA A, BELTRAMO M, PIOMELLI D: Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J. Pharmacol. Exp. Ther. (2001) 298(1):7-14.
   PubMed Web of Science ®Google Scholar
• VARGA K, LAKE K, MARTIN BR, KUNOS G: Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur. J. Pharmacol. (1995) 278(3):279-283.
   PubMed Web of Science ®Google Scholar
• NIEDERHOFFER N, SCHMID K, SZABO B: The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression. Naunyn Schmiedebergs Arch. Pharmacol. (2003) 367(5):434-443.
   PubMed Web of Science ®Google Scholar
• GEBREMEDHIN D, LANGE AR, CAMPBELL WB, HILLARD CJ, HARDER DR: Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am. J. Physiol. (1999) 276(6 Part 2):H2085-H2093.
   PubMed Web of Science ®Google Scholar
• DEUTSCH DG, GOLIGORSKY MS, SCHMID PC et al.: Production and physiological actions of anandamide in the vasculature of the rat kidney. J. Clin. Invest. (1997) 100(6):1538-1546.
   PubMed Web of Science ®Google Scholar
• BATKAI, S, JARAI Z, WAGNER JA et al.: Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat. Med. (2001) 7(7):827-832.
   PubMed Web of Science ®Google Scholar
• WAGNER JA, VARGA K, ELLIS EF, RZIGALINSKI BA, MARTIN BR, KUNOS G: Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature (1997) 390(6659):518-521.
   Google Scholar
• WAGNER, JA, HU K, BAUERSACHS J et al.: Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J. Am. Coll. Cardiol. (2001) 38(7):2048-2054.
   PubMed Web of Science ®Google Scholar
• VARGA, K, WAGNER JA, BRIDGEN DT, KUNOS G: Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J. (1998) 12(11):1035-1044.
   PubMed Web of Science ®Google Scholar
• GODLEWSKI G, MALINOWSKA B, SCHLICKER E: Presynaptic cannabinoid CB(1) receptors are involved in the inhibition of the neurogenic vasopressor response during septic shock in pithed rats. Br. J. Pharmacol. (2004) 142(4):701-708.
   PubMed Web of Science ®Google Scholar
• COTA D, MARSICANO G, TSCHOP M et al.: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. (2003) 112(3):423-431.
   PubMed Web of Science ®Google Scholar
• WILLIAMS CM, KIRKHAM TC: Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl) (1999) 143(3):315-317.
   Google Scholar
• JAMSHIDI N, TAYLOR DA: Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br. J. Pharmacol. (2001) 134(6):1151-1154.
   PubMed Web of Science ®Google Scholar
• KIRKHAM TC, WILLIAMS CM, FEZZA F, DI MARZO V: Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br. J. Pharmacol. (2002) 136(4):550-557.
   PubMed Web of Science ®Google Scholar
• DI MARZO V, GOPARAJU SK, WANG L et al.: Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature (2001) 410(6830):822-825.
   Google Scholar
• RAVINET TRILLOU C, DELGORGE C, MENET C, ARNONE M, SOUBRIE P: CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int. J. Obes. Relat. Metab. Disord. (2004) 28(4):640-648.
   PubMed Web of Science ®Google Scholar
• DE VRIES TJ, DE VRIES W, JANSSEN MC, SCHOFFELMEER AN: Suppression of conditioned nicotine and sucrose seeking by the cannabinoid-1 receptor antagonist SR141716A. Behav. Brain Res. (2005) 161(1):164-168.
   PubMed Web of Science ®Google Scholar
• DE VRIES TJ, SHAHAM Y, HOMBERG JR et al.: A cannabinoid mechanism in relapse to cocaine seeking. Nat. Med. (2001) 7(10):1151-1154.
   PubMed Web of Science ®Google Scholar
• FATTORE L, SPANO MS, COSSU G, DEIANA S, FRATTA W: Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats. Eur. J. Neurosci. (2003) 17(8):1723-1726.
   PubMed Web of Science ®Google Scholar
• ANGGADIREDJA K, NAKAMICHI M, HIRANITA T et al.: Endocannabinoid system modulates relapse to methamphetamine seeking: possible mediation by the arachidonic acid cascade. Neuropsychopharmacology (2004) 29(8):1470-1478.
   Google Scholar
• GALLATE JE, SAHAROV T, MALLET PE, McGREGOR IS: Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist. Eur. J. Pharmacol. (1999) 370(3):233-240.
   PubMed Web of Science ®Google Scholar
• CASTANE A, VALJENT E, LEDENT C, PARMENTIER M, MALDONADO R, VALVERDE O: Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology (2002) 43(5):857-867.
   Google Scholar
• LE FOLL B, GOLDBERG SR: Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences. Neuroreport (2004) 15(13):2139-2143.
   Google Scholar
• RINALDI-CARMONA M, BARTH F, HEAULME M et al.: SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. (1994) 350(2-3):240-244.
   PubMed Web of Science ®Google Scholar
• MacLENNAN, SJ, REYNEN PH, KWAN J, BONHAUS DW: Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. Br. J. Pharmacol. (1998) 124(4):619-622.
   PubMed Web of Science ®Google Scholar
• WHITE R, HILEY CR: The actions of the cannabinoid receptor antagonist, SR 141716A, in the rat isolated mesenteric artery. Br. J. Pharmacol. (1998) 125(4):689-696.
   PubMed Web of Science ®Google Scholar
• CHAYTOR AT, MARTIN PE, EVANS WH, RANDALL MD, GRIFFITH TM: The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication. J. Physiol. (1999) 520(Part 2):539-550.
   PubMed Web of Science ®Google Scholar
• BOYD ST, FREMMING BA: Rimonabant – a selective CB1 antagonist. Ann. Pharmacother. (2005) 39(4):684-690.
   PubMed Web of Science ®Google Scholar
• KANAMALURU V: Lack of effect of rimonabant on the pharmacokinetics of oral contraceptives. Presented at the Annual Meeting of the American College of Clinical Pharmacology, Washington, DC, USA (2005) (Abstract 63).
   Google Scholar
• KANAMALURU V: Lack of effect of rimonabant on the pharmacokinetics and pharmacodynamics of warfarin. Presented at the Annual Meeting of the American College of Clinical Pharmacology, Washington, DC, USA (2005) (Abstract 64).
   Google Scholar
• KANAMALURU V: Lack of effect of rimonabant on the pharmacokinetics of midazolam. Presented at the Annual Meeting of the American College of Clinical Pharmacology, Washington, DC, USA (2005) (Abstract 65).
   Google Scholar
• JBILO O, RAVINET-TRILLOU C, ARNONE M et al.: The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J. (2005) 19(11):1567-1569.
   PubMed Web of Science ®Google Scholar
• RAVINET TRILLOU C, ARNONE M, DELGORGE C et al.: Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2003) 284(2):R345-R353.
   PubMed Web of Science ®Google Scholar
• DESPRES JP, GOLAY A, SJOSTROM L: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. (2005) 353(20):2121-2134.
   PubMed Web of Science ®Google Scholar
• VAN GAAL LF, RISSANEN AM, SCHEEN AJ, ZIEGLER O, ROSSNER S: RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet (2005) 365(9468):1389-1397.
   Google Scholar
• VAN GAAL LF: 2-year data from the RIO-Europe Study: metabolic effects of rimonabant in overweight/obese patients. Presented at the American College of Cardiology Scientific Sessions, Florida, USA (2005).
   Google Scholar
• PI-SUNYER FX: Effect of rimonabant on weight reduction and weight maintenance: RIO-NORTH AMERICA (RIO-NA) trial. Presented at the American College of Cardiology Scientific Sessions, Louisiana, USA (2004).
   Google Scholar
• SCHEEN AJ: Effects of rimonabant in patients with Type 2 diabetes mellitus. Results of the RIO-DIABETES trial. Presented at the American Diabetes Association Scientific Sessions, California, USA (2005).
   Google Scholar
• ANTHENELLI RM: Effects of rimonabant in the reduction of major cardiovascular risk factors. Results from the STRATUS-US trial (smoking cessation in smokers motivated to quit). Presented at the American College of Cardiology Scientific Sessions, Louisiana, USA (2004).
   Google Scholar
• DESPRES J-P: Effects of rimonabant in the reduction of major cardiovascular risk factors. Results from the RIO-LIPIDS trial (weight reducing and metabolic effects in overweight/obese patients with dyslipidemia). Presented at the American College of Cardiology Scientific Sessions, (2004).
   Google Scholar
• MELTZER HY, ARVANITIS L, BAUER D, REIN W: META-Trial Study Group. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am. J. Psychiatry (2004) 161(6):975-984.
   PubMed Web of Science ®Google Scholar